论文部分内容阅读
本文报告用自制的抗-LSpMcab作为试剂,建立了ELISA双夹心法检测病毒性肝炎、系统性红斑狼疮、慢性肾病患者血清中LSp抗原水平,并探讨LSp与抗-LSp、HBeAg、SGPT变化的关系及其临床意义。结果为:正常人血清中未能测到LSp抗原,但在肝细胞损伤时(病毒性或自身免疫性肝病)则可出现LSp阳性(48.2～70％),无症状HBsAg携带者及慢性肾病患者LSp阳性率较低(10～22.2％),二组之间有显著性差异(P<0.01)。抗-LSp阳性者中LSp同时阳性者占68.3％,而抗-LSp阴性者中LSp阳性者只占25.3％(P<0.01)。HBeAg阳性者中LSp阳性者占59.6％,HBeAg阴性者中LSp阳性者占20.4％(P<0.01)。由此表明:(1)血清中LSp的检出与肝细胞损伤有直接关系;(2)LSp的检出率与抗-LSp、HBeAg存在有关;(3)LSp与抗-LSp同时被检出的原因可能是肝病患者免疫功能紊乱、肝细胞持续性进行性损伤所致。
In this paper, the anti-LSpMcab was used as a reagent to establish a double-sandwich ELISA for the detection of serum LSp antigen levels in patients with viral hepatitis, systemic lupus erythematosus and chronic kidney disease and to explore the relationship between LSp and anti-LSp, HBeAg and SGPT And its clinical significance. As a result, LSp antigen was undetectable in normal human serum, but LSp positive (48.2-70%) was found in liver cell damage (viral or autoimmune liver disease), asymptomatic HBsAg carriers and patients with chronic kidney disease The positive rate of LSp was lower (10-22.2%), with significant difference between the two groups (P <0.01). LSp positive patients accounted for 68.3% of the anti-LSp positives, while only 25.3% of the LSp positives were anti-LSp negative (P <0.01). LSp-positive patients accounted for 59.6% of HBeAg-positive patients and 20.4% of HBeAg-negative patients (P <0.01). The results showed that: (1) detection of LSp in serum was directly related to hepatocellular injury; (2) the detection rate of LSp correlated with the existence of anti-LSp and HBeAg; (3) LSp and anti-LSp The reason may be immune disorders in patients with liver disease, sustained progressive damage caused by liver cells.